dihydroxyphenylalanine has been researched along with Dyskinesia, Medication-Induced in 19 studies
Dihydroxyphenylalanine: A beta-hydroxylated derivative of phenylalanine. The D-form of dihydroxyphenylalanine has less physiologic activity than the L-form and is commonly used experimentally to determine whether the pharmacological effects of LEVODOPA are stereospecific.
dopa : A hydroxyphenylalanine carrying hydroxy substituents at positions 3 and 4 of the benzene ring.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The long-term use of LD is limited by the development of L-DOPA-induced dyskinesias and dystonia." | 1.39 | The combination of oral L-DOPA/rimonabant for effective dyskinesia treatment and cytological preservation in a rat model of Parkinson's disease and L-DOPA-induced dyskinesia. ( Aley-Medina, P; Anaya-Martínez, V; Avila-Costa, MR; Espinosa-Villanueva, J; García-Ruiz, R; Gutiérrez-Valdez, AL; Montiel-Flores, E; Reynoso-Erazo, L; Sánchez-Betancourt, J; Torres-Esquivel, C; Tron-Alvarez, R, 2013) |
| " We retrospectively analyzed data from 17 stable HP rhesus monkeys treated long-term with chronic intermittent dosing of levodopa (LD) in an attempt to induce choreoathetoid and dystonic dyskinesias." | 1.37 | Dyskinesias do not develop after chronic intermittent levodopa therapy in clinically hemiparkinsonian rhesus monkeys. ( Bakay, RA; Deogaonkar, M; Lieu, CA; Subramanian, T, 2011) |
| "Levodopa caused an increase in plasma growth hormone concentration in 30 subjects." | 1.26 | Plasma DOPA levels and growth hormone response to levodopa in parkinsomism. ( Galea-Debono, A; Jenner, P; Marsden, CD; Parkes, JD; Tarsy, D; Walters, J, 1977) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (31.58) | 18.7374 |
| 1990's | 5 (26.32) | 18.2507 |
| 2000's | 4 (21.05) | 29.6817 |
| 2010's | 3 (15.79) | 24.3611 |
| 2020's | 1 (5.26) | 2.80 |
| Authors | Studies |
|---|---|
| Speck, AE | 1 |
| Aguiar, AS | 1 |
| Ferreira, SG | 1 |
| Silva, HB | 1 |
| Tomé, ÂR | 1 |
| Agostinho, P | 1 |
| Cunha, RA | 1 |
| Prediger, RD | 1 |
| Gutiérrez-Valdez, AL | 1 |
| García-Ruiz, R | 1 |
| Anaya-Martínez, V | 1 |
| Torres-Esquivel, C | 1 |
| Espinosa-Villanueva, J | 1 |
| Reynoso-Erazo, L | 1 |
| Tron-Alvarez, R | 1 |
| Aley-Medina, P | 1 |
| Sánchez-Betancourt, J | 1 |
| Montiel-Flores, E | 1 |
| Avila-Costa, MR | 1 |
| Alcacer, C | 1 |
| Charbonnier-Beaupel, F | 1 |
| Corvol, JC | 1 |
| Girault, JA | 1 |
| Hervé, D | 1 |
| Lieu, CA | 1 |
| Deogaonkar, M | 1 |
| Bakay, RA | 1 |
| Subramanian, T | 1 |
| Schönfeldt-Lecuona, C | 1 |
| Juengling, FD | 1 |
| Connemann, BJ | 1 |
| Reske, SN | 1 |
| Spitzer, M | 1 |
| Kassubek, J | 1 |
| Sossi, V | 1 |
| de la Fuente-Fernández, R | 1 |
| Schulzer, M | 1 |
| Adams, J | 1 |
| Stoessl, J | 1 |
| Natesan, S | 1 |
| Svensson, KA | 1 |
| Reckless, GE | 1 |
| Nobrega, JN | 1 |
| Barlow, KB | 1 |
| Johansson, AM | 1 |
| Kapur, S | 1 |
| Wöller, W | 2 |
| Tegeler, J | 2 |
| Bennett, JP | 1 |
| Landow, ER | 1 |
| Schuh, LA | 1 |
| Narabayashi, H | 1 |
| Blanchet, PJ | 1 |
| Gomez-Mancilla, B | 1 |
| Bédard, PJ | 1 |
| Brooks, DJ | 1 |
| Perret, J | 1 |
| Feuerstein, C | 1 |
| Pellat, J | 1 |
| Serre, F | 1 |
| Gavend, M | 1 |
| Tanche, M | 1 |
| Galea-Debono, A | 1 |
| Jenner, P | 1 |
| Marsden, CD | 2 |
| Parkes, JD | 1 |
| Tarsy, D | 1 |
| Walters, J | 1 |
| Mierau, J | 1 |
| Schingnitz, G | 1 |
| Nygaard, TG | 1 |
| Fahn, S | 1 |
| Nasrallah, HA | 1 |
| Dunner, FJ | 1 |
| McCalley-Whitters, M | 1 |
| Smith, RE | 1 |
| Albani, C | 1 |
| Asper, R | 1 |
| Baumgartner, G | 1 |
3 reviews available for dihydroxyphenylalanine and Dyskinesia, Medication-Induced
| Article | Year |
|---|---|
The neural mechanisms and progressive nature of symptoms of Parkinson's disease--based on clinical, neurophysiological and morphological studies.
Topics: Dihydroxyphenylalanine; Disease Progression; Dyskinesia, Drug-Induced; Humans; Levodopa; Movement Di | 1995 |
DOPA-induced "peak dose" dyskinesia: clues implicating D2 receptor-mediated mechanisms using dopaminergic agonists in MPTP monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dihydroxyphenylalanine; Dopamine Agonists; Dy | 1995 |
PET studies and motor complications in Parkinson's disease.
Topics: Antiparkinson Agents; Brain; Corpus Striatum; Dihydroxyphenylalanine; Dyskinesia, Drug-Induced; Fluo | 2000 |
1 trial available for dihydroxyphenylalanine and Dyskinesia, Medication-Induced
| Article | Year |
|---|---|
Pharmacologic probes of neurotransmitter systems in tardive dyskinesia: implications for clinical management.
Topics: 5-Hydroxytryptophan; Adult; Aged; Choline; Clinical Trials as Topic; Dihydroxyphenylalanine; Dopamin | 1986 |
15 other studies available for dihydroxyphenylalanine and Dyskinesia, Medication-Induced
| Article | Year |
|---|---|
Exercise decreases aberrant corticostriatal plasticity in an animal model of l-DOPA-induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Benserazide; Cerebral Cortex; Corpus Striatum; Dihydroxyphenylalanine | 2021 |
The combination of oral L-DOPA/rimonabant for effective dyskinesia treatment and cytological preservation in a rat model of Parkinson's disease and L-DOPA-induced dyskinesia.
Topics: Administration, Oral; Animals; Cannabinoid Receptor Antagonists; Corpus Striatum; Dihydroxyphenylala | 2013 |
Mitogen- and stress-activated protein kinase 1 is required for specific signaling responses in dopamine-denervated mouse striatum, but is not necessary for L-DOPA-induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Dihydroxyphenylalanine; Dopaminergic Neurons; Dyskin | 2014 |
Dyskinesias do not develop after chronic intermittent levodopa therapy in clinically hemiparkinsonian rhesus monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Carot | 2011 |
Complete dopamine D2 receptor occupancy without extrapyramidal side effects under benperidol.
Topics: Adult; Basal Ganglia; Benperidol; Carbon Radioisotopes; Clozapine; Dihydroxyphenylalanine; Dyskinesi | 2004 |
Age-related differences in levodopa dynamics in Parkinson's: implications for motor complications.
Topics: Adult; Age Factors; Age of Onset; Aged; Antiparkinson Agents; Dihydroxyphenylalanine; Dopamine Agent | 2006 |
The dopamine stabilizers (S)-(-)-(3-methanesulfonyl-phenyl)-1-propyl-piperidine [(-)-OSU6162] and 4-(3-methanesulfonylphenyl)-1-propyl-piperidine (ACR16) show high in vivo D2 receptor occupancy, antipsychotic-like efficacy, and low potential for motor sid
Topics: Animals; Antipsychotic Agents; Avoidance Learning; Binding, Competitive; Dihydroxyphenylalanine; Dop | 2006 |
[Tardive dyskinesia: clinical picture, prevalence, and pathophysiology].
Topics: Age Factors; Antipsychotic Agents; Diagnosis, Differential; Dihydroxyphenylalanine; Dyskinesia, Drug | 1983 |
[Therapeutic measures in tardive dyskinesia].
Topics: Age Factors; Amantadine; Antipsychotic Agents; Baclofen; Benzodiazepines; Bromocriptine; Deanol; Dih | 1983 |
Suppression of dyskinesias in advanced Parkinson's disease. II. Increasing daily clozapine doses suppress dyskinesias and improve parkinsonism symptoms.
Topics: Aged; Clozapine; Dihydroxyphenylalanine; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; | 1993 |
[Results of determination of plasma methoxydopa in parkinsonian patients with or without dyskinesia induced by L-Dopa].
Topics: Aged; Dihydroxyphenylalanine; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; | 1977 |
Plasma DOPA levels and growth hormone response to levodopa in parkinsomism.
Topics: Adult; Aged; Dihydroxyphenylalanine; Dyskinesia, Drug-Induced; Female; Growth Hormone; Humans; Levod | 1977 |
Biochemical and pharmacological studies on pramipexole, a potent and selective dopamine D2 receptor agonist.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Benzothiazoles; Corpus Striatum; Dihydroxyphenylalanine; Do | 1992 |
Dopa-responsive dystonia: long-term treatment response and prognosis.
Topics: Adolescent; Adult; Carbamazepine; Child; Child, Preschool; Depression; Dihydroxyphenylalanine; Disab | 1991 |
[Long-term problems of levodopa therapy in Parkinson disease].
Topics: Adult; Aged; Chromatography, High Pressure Liquid; Dihydroxyphenylalanine; Dyskinesia, Drug-Induced; | 1987 |